Marks Group Wealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Marks Group Wealth Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,800	Closed	-$205K	–	298
2022 Q4	$205K	Buy	+1,800	New	+$150K	0.03%	270
2022 Q2	–	Sell	-2,127	Closed	-$224K	–	317
2022 Q1	$224K	Buy	2,127 +221	+12%	+$21.5K	0.03%	286
2021 Q4	$205K	Hold	1,906	–	–	0.03%	296
2021 Q3	$209K	Buy	+1,906	New	+$198K	0.03%	279

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marks Group Wealth Management's HZNP Position: Q1 2023 in Review

Marks Group Wealth Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 1,800 shares — an estimated $205K sold.

Marks Group Wealth Management first reported a position in HZNP in Q3 2021 and held it in 4 quarters. The position peaked at $224K in Q1 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Marks Group Wealth Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Marks Group Wealth Management sold 1,800 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $205K.
Marks Group Wealth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 4 quarters.
Marks Group Wealth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $224K in Q1 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Marks Group Wealth Management's 13F filing for Q1 2023, filed 3 May 2023.